Catechol O-methyltransferase
From Proteopedia
(Difference between revisions)
(6 intermediate revisions not shown.) | |||
Line 11: | Line 11: | ||
==Structural highlights == | ==Structural highlights == | ||
- | *<scene name='55/551215/Cv/ | + | *<scene name='55/551215/Cv/4'>Active site of human catechol O-methyltransferase complex with SAM and dinitrocatechol</scene> (PDB entry [[3a7e]]). Water molecule is shown as red sphere. |
- | + | ||
== 3D Structures of catechol O-methyltransferase == | == 3D Structures of catechol O-methyltransferase == | ||
+ | [[Catechol O-methyltransferase 3D structures]] | ||
- | + | </StructureSection> | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | **[[2zth]] – rCOMT + SAM <BR /> | ||
- | **[[3u81]], [[4pyn]], [[4pyo]] – rCOMT (mutant) + SAH<BR /> | ||
- | **[[4pyq]] – rCOMT (mutant) + ureido-benzamidine<BR /> | ||
- | **[[1vid]] – rCOMT + SAM + dinitrocatechol <BR /> | ||
- | **[[1jr4]], [[3hvh]], [[3hvi]], [[3hvj]], [[3hvk]], [[3a7d]], [[3nw9]], [[3nwb]], [[3nwe]] – rCOMT + inhibitor<BR /> | ||
- | **[[4p7k]], [[4pyl]] – rCOMT + sinefungin<BR /> | ||
- | **[[3oe4]], [[3oe5]], [[3ozr]], [[3ozs]], [[3ozt]], [[3r6t]] – rCOMT (mutant) + inhibitor<BR /> | ||
- | **[[1h1d]], [[2cl5]], [[2zvj]], [[3s68]] – rCOMT + inhibitor + SAM<BR /> | ||
- | **[[2avd]] – hCOMT + SAM – human <BR /> | ||
- | **[[3bwm]], [[3a7e]] – hCOMT + SAM + dinitrocatechol <BR /> | ||
- | **[[3bwy]], [[4xuc]] – hCOMT (mutant) + SAM + dinitrocatechol <BR /> | ||
- | **[[4p58]] – mCOMT + inhibitor <BR /> | ||
- | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] |
Current revision
|
References
- ↑ Tsuji E, Okazaki K, Isaji M, Takeda K. Crystal structures of the Apo and Holo form of rat catechol-O-methyltransferase. J Struct Biol. 2008 Dec 10. PMID:19111934 doi:S1047-8477(08)00293-1
- ↑ Muller T. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Drugs. 2015 Feb;75(2):157-74. doi: 10.1007/s40265-014-0343-0. PMID:25559423 doi:http://dx.doi.org/10.1007/s40265-014-0343-0